NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMSW) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 13,300 shares, a growth of 66.3% from the March 31st total of 8,000 shares. Based on an average daily volume of 12,500 shares, the short-interest ratio is presently 1.1 days.

Institutional Trading of NewAmsterdam Pharma

An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC increased its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) by 270.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 137,000 shares of the company’s stock after buying an additional 100,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $260,000 as of its most recent filing with the Securities and Exchange Commission.

NewAmsterdam Pharma Stock Up 24.3 %

NewAmsterdam Pharma stock traded up $2.36 during trading hours on Monday, hitting $12.09. The stock had a trading volume of 93 shares, compared to its average volume of 16,534. NewAmsterdam Pharma has a 1-year low of $0.99 and a 1-year high of $14.67. The stock’s fifty day moving average is $10.49 and its two-hundred day moving average is $6.43.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.